Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis
Abdul Fatah Malik, Fnu Kashish, Fnu Shivani, Somesh Kumar, Vanesha Kumari, Abdul Haseeb, Ahmad Mujtaba, Abdur Raheem, Syed Muhammad Sinaan Ali, Usama Saleh, Tagwa Kalool Fadlalla Ahmad · 2026
Read Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis by Abdul Fatah Malik, Fnu Kashish, Fnu Shivani, Somesh Kumar, Vanesha Kumari, Abdul Haseeb, Ahmad Mujtaba, Abdur Raheem, Syed Muhammad Sinaan Ali, Usama Saleh, Tagwa Kalool Fadlalla Ahmad (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13225597.txt.
Description
Malik and co-authors present a 2026 review pooling trials of triple versus dual pill therapy for type 2 diabetes. The triple mix joins metformin with two newer drug families, SGLT-2 and DPP-4 blockers. Eight randomized trials with 2,606 patients were gathered from four databases under standard review rules. Blood sugar, fasting glucose, weight, target reach, and side effects were the measures.
Triple therapy cut the long-term sugar marker HbA1c by a firm margin over dual therapy, the pooled result showed. Random-effects models guarded against study-to-study spread. The authors weigh whether the extra drug's gain justifies its place before insulin enters the picture for patients failing two drugs.
Catalog record
| CREATOR | Abdul Fatah Malik, Fnu Kashish, Fnu Shivani, Somesh Kumar, Vanesha Kumari, Abdul Haseeb, Ahmad Mujtaba, Abdur Raheem, Syed Muhammad Sinaan Ali, Usama Saleh, Tagwa Kalool Fadlalla Ahmad |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |